Quantum Molecular Resonance Effects on Patients With Dry Eye Disease: A Randomized Controlled Trial

Area of Science:

• Ophthalmology
• Medical Technology

Background:

• Dry eye disease (DED) is a prevalent condition affecting millions worldwide.
• Current treatments for DED offer variable efficacy and can have side effects.

Purpose of the Study:

• To evaluate the efficacy and safety of quantum molecular resonance (QMR) therapy for treating dry eye disease.
• To assess QMR's impact on DED symptoms and clinical signs.

Main Methods:

• A 2-year, double-blind, randomized controlled trial was conducted.
• Participants received weekly QMR treatment or placebo for 4 weeks using the Rexon-Eye device.
• Outcomes included Ocular Surface Disease Index (OSDI) for symptoms and meibomian gland dysfunction (MGD) score, tear break-up time (TBUT), corneal staining, Schirmer test, and visual acuity for clinical signs.

Main Results:

• Forty patients (20 per group) completed the study.
• The QMR group showed significant improvement in OSDI scores (P < 0.001) and MGD scores (P = 0.006).
• Significant improvement was also observed in corneal staining (P = 0.045) in the QMR group, with no significant changes in the placebo group for these measures. TBUT, visual acuity, and Schirmer scores did not differ significantly between groups. No adverse events were reported.

Conclusions:

• High-frequency electrotherapy, such as QMR, demonstrates a positive effect on both symptoms and clinical signs of dry eye disease.
• This emerging technology presents a potential new therapeutic option for managing dry eye.
• Further research is warranted to establish QMR's long-term efficacy and optimal use in DED management.